ArriVent BioPharma (AVBP) Operating Leases (2023 - 2026)

ArriVent BioPharma (AVBP) has 3 years of Operating Leases data on file, last reported at $320000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $320000.0; the trailing twelve-month figure through Mar 2026 stood at $320000.0 (changed N/A YoY), and the FY2024 full-year result was $14000.0, down 92.09% from the prior year.
• Operating Leases grew to $320000.0 in Q1 2026, from $14000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $320000.0 in Q1 2026 to a low of $14000.0 in Q4 2024.
• A 3-year average of $133833.3 and a median of $118000.0 in 2024 frame the typical range for Operating Leases.
• Peak annual rise in Operating Leases reached 92.09% in 2024, while the deepest fall reached 92.09% in 2024.
• Tracing AVBP's Operating Leases over 3 years: stood at $177000.0 in 2023, then sank by 92.09% to $14000.0 in 2024, then jumped by 2185.71% to $320000.0 in 2026.
• Business Quant data shows AVBP's Operating Leases at $320000.0 in Q1 2026, $14000.0 in Q4 2024, and $56000.0 in Q3 2024.